Sincalide

Cholecystokinin Analog (C Terminal Octapeptide Of Cholecystokinin)Rx: PrescriptionCompound: Approved

Also known as: C-CCK-8, Caerulein analog, CCK-8, Cholecystokinin octapeptide, Kinevac

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

Sincalide (Kinevac) is an FDA-approved synthetic cholecystokinin analog used diagnostically to stimulate gallbladder contraction for cholecystography and hepatobiliary scintigraphy, and to stimulate pancreatic secretion for collection and analysis of duodenal contents. It is also used to accelerate transit of barium through the small intestine.

Mechanism of Action

Sincalide is a synthetic C-terminal octapeptide of cholecystokinin (CCK-8) that binds to CCK receptors (CCK1/CCKA) on gallbladder smooth muscle, causing contraction and bile ejection; also stimulates pancreatic enzyme secretion and gastric motility.

Routes of Administration

Intravenous

Goals & Uses

  • Assessment of gallbladder ejection fractionDiagnosticHigh
  • Acceleration of small bowel barium transitDiagnostic ImagingModerate
  • Stimulation of pancreatic enzyme secretionDiagnosticHigh
  • Gallbladder contraction for cholecystographyDiagnostic ImagingHigh

Contraindications

  • Intestinal obstructionGastrointestinalHigh
  • Hypersensitivity to sincalide or CCK analogsAllergyHigh
  • PregnancyPopulationModeratePotential fetal risk or insufficient safety data

Adverse Effects

  • Abdominal discomfort/crampingGastrointestinalCommon
  • HypotensionCardiovascularRareLow blood pressure
  • FlushingVascularUncommonWarmth and redness of the skin
  • NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
  • VomitingGastrointestinalUncommonForceful expulsion of stomach contents
  • DizzinessNeurologicUncommonFeeling faint, lightheaded, or unsteady

Drug Interactions

  • Anticholinergic agentsLow
  • Opioid analgesicsModerate

Population Constraints

  • PregnancyReproductive SafetyRelative
  • Pediatric patientsAgeRelative
  • Patients with suspected acute pancreatitisGastrointestinalRelative

Regulatory Status

  • European UnionUnknownAvailability may vary by EU member state; not widely marketed as a standard product in the EU.
  • United StatesApprovedApproved: Stimulation of gallbladder contraction for cholecystography, Stimulation of pancreatic secretion for diagnostic purposes, Acceleration of barium small intestinal transitApproved by FDA; marketed as Kinevac by Bracco Diagnostics.
  • United KingdomUnknownLimited marketing authorization data available for the UK.

Approved by the FDA for diagnostic use. Administered intravenously under medical supervision. Not for therapeutic use.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack